Surrozen, Inc. (SRZN)
Automate Your Wheel Strategy on SRZN
With Tiblio's Option Bot, you can configure your own wheel strategy including SRZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRZN
- Rev/Share 2.9369
- Book/Share 1.5639
- PB 6.3301
- Debt/Equity 1.4043
- CurrentRatio 10.018
- ROIC -0.2462
- MktCap 84769542.0
- FreeCF/Share -5.0185
- PFCF -4.6559
- PE -0.4396
- Debt/Assets 0.0694
- DivYield 0
- ROE 82.1765
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SRZN | H.C. Wainwright | -- | Buy | -- | $32 | Jan. 30, 2025 |
| Upgrade | SRZN | Guggenheim | Neutral | Buy | -- | $45 | Jan. 3, 2025 |
News
Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Surrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read More
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases Announces an oversubscribed financing of $175 million in gross proceeds, which funds multiple ophthalmology programs through phase 1 safety, tolerability and efficacy studies Company discontinues clinical development of SZN-043 in severe alcohol associated hepatitis SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that the company will focus its Wnt biology expertise …
Read More
About Surrozen, Inc. (SRZN)
- IPO Date 2021-01-11
- Website https://www.surrozen.com
- Industry Biotechnology
- CEO Mr. Craig C. Parker M.B.A.
- Employees 40